

AUTHOR INDEX

- Abu-Rustum, N.R., 235
 Agajanian, C., 235
 Ahlert, T., 677
 Alvarez, R.D., 397
 Auersperg, N., 281

 Bajorin, D.F., 131, 186
 Balmaceda, C., 243
 Barnes, M.N., 397
 Bartik, M.M., 27
 Berd, D., 605, 646
 Beyer, J., 174, 215
 Boente, M.P., 326
 Bookman, M.A., 381
 Bornstein, S., 1
 Borowitz, M.J., 6
 Byrd, J.C., 4, 65

 Cao, S., 584
 Casey, M.J., 265
 Chaganti, R.S.K., 133
 Chan, A.D., 611
 Chandawarkar, R., 654
 Cheson, B.D., 42
 Chi, D.S., 326
 Corn, B., 361
 Crawford, J., 552
 Cullen, M., 154
 Curiel, D.T., 397

 Daly, M., 255
 de Lima, M., 107
 DeMaio, M.D., 492
 Diehl, L.F., 80
 Dighiero, G., 34
 DiGiuseppe, J.A., 6
 Dorr, V.J., 562
 Dunton, C., 646

 Edelson, M.I., 281

 Finlay, J., 243
 Flinn, I.W., 4, 60
 Foster, R.S., 145
 Friedlander, M.L., 305

 Gerhards, R., 677
 Giles, F.J., 117
 Giwercman, A., 224
 Glaspy, J.A., 571
 Godwin, A.K., 265
 Golomb, H.M., 419, 476
 Gospadorowicz, M.K., 160
 Gralla, R.J., 577
 Grever, M.R., 4, 65
 Grim, J., 397

 Hagmuller, E., 677
 Hamilton, T.C., 281
 Haridas, K., 584
 Hausheer, F.H., 584
 Hays, K., 75

 Herr, H., 203
 Herrold-Mende, C., 677
 Horwich, A., 154
 Hoskins, W.J., 326

 Jacobs, I., 315
 Jewitt, M.A.S., 160
 Jilani, S.M., 571
 Johnson, S.W., 281
 Johnston, E.M., 552
 Juliusson, G., 19

 Kaern, J., 372
 Kairys, J., 646
 Kanter, P., 584
 Kast, W.M., 697
 Kay, N.E., 27
 Keating, M.J., 107, 117
 Ketchum, L.H., 80
 Koeppen, H., 421

 Lanciano, R., 361
 Laport, G.F., 503
 Le Beau, M.M., 447
 Lerner, S., 107
 Liebowitz, D.N., 419, 461, 492
 Livingston, P., 636
 Lynch, H.T., 265
 Lynch, J., 265
 Lyons, S.F., 461

 Maguire Jr, H.C., 646
 Maloum, K., 34
 Markman, M., 356, 522
 Martinez, N., 584
 Mastrangelo, M.J., 1, 646
 McCaffrey, J.A., 186
 McCartney, S., 75
 McGuire, W.P., 340
 Menoret, A., 654
 Merrup, M., 19
 Mikhak, B., 661
 Mitchell, M.S., 623
 Modak, S., 243
 Mok, S.C., 281
 Morrison, V.A., 98
 Morton, D.L., 611
 Motzer, R.J., 131, 194
 Murali, D., 584
 Murty, V.S., 133

 Nichols, C.R., 210

 O'Brien, S.M., 117
 O'Brien, S., 107
 Orams, G.I., 255
 Ong, S.T., 447
 Ozols, R.F., 340

 Pecorelli, S., 335
 Perry, M.C., 521

 Petersen, P.M., 224
 Petluru, P., 584
 Pritsch, O., 34
 Probstle, T., 677

 Rai, K.R., 65
 Rancourt, C., 397
 Randall, M., 361
 Reddy, D., 584
 Reddy, S., 361
 Reed, J.C., 11
 Robertson, M.W.III, 397
 Rorth, M., 224
 Rosenthal, A., 315
 Roth, B.J., 145
 Rudin, C.M., 435
 Rustum, Y., 584

 Sato, T., 646
 Sausville, E.A., 65
 Saxe, J.D., 584
 Saxman, S., 210
 Schilder, R.J., 349
 Schirmacher, V., 677
 Schmoll, H.J., 174
 Schreiber, H., 697
 Seetharamulu, P., 584
 Shea, T.C., 349
 Sheinfeld, J., 203
 Siegal, G.P., 397
 Siegert, W., 215
 Simons, J.W., 661
 Skakkebaek, N.E., 224
 Speyer, J., 525
 Steiner, H.H., 677
 Stenning, S.P., 154
 Sturgeon, J.E.G., 160

 Thompson, C.B., 435
 Toner, G.C., 194
 Troé, C., 372

 Vardiman, J.W., 421
 Velders, M.P., 697
 Vogelsang, G., 60
 Vose, J.M., 483

 Wang, M., 397
 Wasserheit, C., 525
 Welker, D., 27
 White, T.E.K., 265
 Williams, S.D., 407
 Wilkes, J.D., 538
 Williams, S.F., 419, 503

 Yao, S., 584
 Yarbrow, J.W., 1
 Young, R.C., 335

 Zhao, M., 584
 Zukowski, A., 584
 Zweibel, J.A., 42

AUTHOR INDEX

- Abu-Rustum, N.R., 235
 Agajanian, C., 235
 Ahlert, T., 677
 Alvarez, R.D., 397
 Auersperg, N., 281

 Bajorin, D.F., 131, 186
 Balmaceda, C., 243
 Barnes, M.N., 397
 Bartik, M.M., 27
 Berd, D., 605, 646
 Beyer, J., 174, 215
 Boente, M.P., 326
 Bookman, M.A., 381
 Bornstein, S., 1
 Borowitz, M.J., 6
 Byrd, J.C., 4, 65

 Cao, S., 584
 Casey, M.J., 265
 Chaganti, R.S.K., 133
 Chan, A.D., 611
 Chandawarkar, R., 654
 Cheson, B.D., 42
 Chi, D.S., 326
 Corn, B., 361
 Crawford, J., 552
 Cullen, M., 154
 Curiel, D.T., 397

 Daly, M., 255
 de Lima, M., 107
 DeMaio, M.D., 492
 Diehl, L.F., 80
 Dighiero, G., 34
 DiGiuseppe, J.A., 6
 Dorr, V.J., 562
 Dunton, C., 646

 Edelson, M.I., 281

 Finlay, J., 243
 Flinn, I.W., 4, 60
 Foster, R.S., 145
 Friedlander, M.L., 305

 Gerhards, R., 677
 Giles, F.J., 117
 Giwercman, A., 224
 Glaspy, J.A., 571
 Godwin, A.K., 265
 Golomb, H.M., 419, 476
 Gospadorowicz, M.K., 160
 Gralla, R.J., 577
 Grever, M.R., 4, 65
 Grim, J., 397

 Hagmuller, E., 677
 Hamilton, T.C., 281
 Haridas, K., 584
 Hausheer, F.H., 584
 Hays, K., 75

 Herr, H., 203
 Herrold-Mende, C., 677
 Horwich, A., 154
 Hoskins, W.J., 326

 Jacobs, I., 315
 Jewitt, M.A.S., 160
 Jilani, S.M., 571
 Johnson, S.W., 281
 Johnston, E.M., 552
 Juliusson, G., 19

 Kaern, J., 372
 Kairys, J., 646
 Kanter, P., 584
 Kast, W.M., 697
 Kay, N.E., 27
 Keating, M.J., 107, 117
 Ketchum, L.H., 80
 Koeppen, H., 421

 Lanciano, R., 361
 Laport, G.F., 503
 Le Beau, M.M., 447
 Lerner, S., 107
 Liebowitz, D.N., 419, 461, 492
 Livingston, P., 636
 Lynch, H.T., 265
 Lynch, J., 265
 Lyons, S.F., 461

 Maguire Jr, H.C., 646
 Maloum, K., 34
 Markman, M., 356, 522
 Martinez, N., 584
 Mastrangelo, M.J., 1, 646
 McCaffrey, J.A., 186
 McCartney, S., 75
 McGuire, W.P., 340
 Menoret, A., 654
 Merrup, M., 19
 Mikhak, B., 661
 Mitchell, M.S., 623
 Modak, S., 243
 Mok, S.C., 281
 Morrison, V.A., 98
 Morton, D.L., 611
 Motzer, R.J., 131, 194
 Murali, D., 584
 Murty, V.S., 133

 Nichols, C.R., 210

 O'Brien, S.M., 117
 O'Brien, S., 107
 Orams, G.I., 255
 Ong, S.T., 447
 Ozols, R.F., 340

 Pecorelli, S., 335
 Perry, M.C., 521

 Petersen, P.M., 224
 Petluru, P., 584
 Pritsch, O., 34
 Probstle, T., 677

 Rai, K.R., 65
 Rancourt, C., 397
 Randall, M., 361
 Reddy, D., 584
 Reddy, S., 361
 Reed, J.C., 11
 Robertson, M.W.III, 397
 Rorth, M., 224
 Rosenthal, A., 315
 Roth, B.J., 145
 Rudin, C.M., 435
 Rustum, Y., 584

 Sato, T., 646
 Sausville, E.A., 65
 Saxe, J.D., 584
 Saxman, S., 210
 Schilder, R.J., 349
 Schirmacher, V., 677
 Schmoll, H.J., 174
 Schreiber, H., 697
 Seetharamulu, P., 584
 Shea, T.C., 349
 Sheinfeld, J., 203
 Siegal, G.P., 397
 Siegert, W., 215
 Simons, J.W., 661
 Skakkebaek, N.E., 224
 Speyer, J., 525
 Steiner, H.H., 677
 Stenning, S.P., 154
 Sturgeon, J.E.G., 160

 Thompson, C.B., 435
 Toner, G.C., 194
 Troé, C., 372

 Vardiman, J.W., 421
 Velders, M.P., 697
 Vogelsang, G., 60
 Vose, J.M., 483

 Wang, M., 397
 Wasserheit, C., 525
 Welker, D., 27
 White, T.E.K., 265
 Williams, S.D., 407
 Wilkes, J.D., 538
 Williams, S.F., 419, 503

 Yao, S., 584
 Yarbrow, J.W., 1
 Young, R.C., 335

 Zhao, M., 584
 Zukowski, A., 584
 Zweibel, J.A., 42

SUBJECT INDEX

- ABVD chemotherapy, in HD, 477-478
 Acetaminophen, relative toxicity of, 597
 Actinomycin
 alopecia induced by, 563
 emesis risk of, 578
 oral mucositis due to, 541
 Adeno-associated virus, 667
 as gene transfer vector, 665
 Adenovirus, as gene transfer vector, 665
 Adenovirus type 5, 666
 Adhesion molecule, 680-685
 Adhesions, in ovarian cancer, 384-385
 Adnexal mass, laparoscopic management of, 327
 Adoptive cellular immunotherapy, in ovarian cancer, 386-387
 Adult T-cell leukemia, 7
 Adult T-cell leukemia-lymphoma, 468-469
 HTLV-1 and, 467
 Adult T-cell lymphoma, peripheral blood involvement in, 7
 Age
 as oral mucositis risk factor, 540
 as prognostic factor, in chronic lymphocytic leukemia, 44
 AIDS, lymphoma associated with, 456-457
 AIDS-associated non-Hodgkin's lymphoma, 465-466
 antiretroviral therapy in, 496
 clinical manifestations of, 492-493
 epidemiology in, 492
 hematopoietic growth factor support in, 495
 pathogenesis of, 493-494
 systemic, treatment of, 494-495
 AKT2, 265-270
 hypothetical role of, 266
 Alkeran, emesis risk of, 578
 Allelic deletion, in germ cell tumors, 135-136
 Allelotyping, in germ cell tumors, 137-138
 Allogeneic lysate
 experience with, 625-626
 immune response to, 632-633
 Allogeneic lysate vaccine, for melanoma, 623-635
 Allogeneic vaccine(s)
 background of, 611-612
 clinical trials of, 613-619
 Allopurinol, in oral mucositis, 542
 Alopecia
 cancer-related, practitioner's guide to, 562-570
 radiation-induced, 568
 Alpha fetoprotein, 211
 posttreatment, in germ cell tumors, 182-183
 Alpha-tocopherol, 565-566
 in hair loss, 567
 Amifostine, 587-590
 administration of, 589-590
 future uses of, 523-524
 in cisplatin toxicity reduction, 522-524
 relative toxicity of, 597
 Amifostine, cisplatin, cyclophosphamide regimen, phase III trial of, 522-523
 Amphotericin B, in oral mucositis, 544
 Amscrine
 alopecia induced by, 563
 oral mucositis due to, 541
 Analgesics, in mucositis therapy, 546-547
 Anaplastic large B-cell lymphoma, 426
 Anaplastic large cell lymphoma, 428-429
 Anemia
 autoimmune hemolytic, see Autoimmune hemolytic anemia
 cancer-associated, etiology of, 571
 chemotherapy-associated, epoetin alfa in, 571-576
 as prognostic factor, 45
 Anesthetic, topical, in mucositis therapy, 546
 Angiogenesis, in ovarian cancer, 384-385
 Angiotensin-converting enzyme inhibitors, cardiotoxicity and, 534
 Anthracycline
 in chronic lymphocytic leukemia, 68
 analogs of, 529
 Anthracycline toxicity, 525
 anthracycline analogs and, 529
 biochemistry of, 525
 in children, 526-527
 clinical, 525-527
 liposomal anthracycline delivery and, 529-530
 pathology of, 527
 reduction of, 525-537, 529
 Antibiotics, in oral mucositis, 544
 Antibody(ies)
 actions of, mechanisms of, 639
 induced by vaccines, basis for, 636-637
 Antibody-dependent cell-mediated cytotoxicity, 32, 639
 Antiemetic agents, 579
 investigative, 582
 Antiemetic regimens, by emetic risk group, 579, 580-581
 Antiemetic therapy, 577-583
 Antigen, tumor-rejection, search for, 654-655
 Antigen modulation, in ovarian cancer, 386
 Antigen-presenting cell, 670, 682
 Antimyosin scintigraphy, for cardiotoxicity, 528
 Apoptosis, dysregulation of, in B-cell chronic lymphocytic leukemia, 14-15
 AS101, 566
 Aspirin, relative toxicity of, 597
 Ataxia-telangiectasia gene, mutations of, 14
 Atomic absorption spectrometry, 586
 Autoantibodies, natural, activity of, 35-36
 Autoimmune disease, chronic lymphocytic leukemia and, 80-97
 Autoimmune hemolytic anemia
 classification of, 82
 clinical features of, 83
 cyclosporine A in, 87, 91
 cytotoxic agents in, 85-86, 91
 danazol in, 87, 91
 definition of, 82
 immunoabsorption, 87, 91
 intravenous immunoglobulin in, 86, 91
 pathophysiology of, 82-83

- Autoimmune hemolytic anemia (*Continued*)
 plasma exchange in, 87, 91
 splenectomy in, 85, 91
 splenic irradiation in, 86-87, 91
 steroid therapy for, 85, 91
 therapy for, 91
 transfusion therapy in, 88, 91
 treatment overview in, 83-85
 treatment-related, 88-89
 vincristine-loaded platelets in, 87-88, 91
- Autoimmune phenomena
 in B-cell chronic lymphocytic leukemia, 38
 basic biology of, 34-41
 in chronic lymphocytic leukemia, 80-82
- Autoimmune thrombocytopenia
 clinical features of, 92-93
 definition of, 92
 pathophysiology of, 92
 therapy of, 92
- Autologous tumor vaccine-Newcastle disease virus
 production of, 678-680
 rationale for, 688
- Autoreactive repertoire, 35-36
 B-cell malignancies and, 36
- Avipox virus, as gene transfer vector, 665
- B cell
 abnormal autoreactive, 36-38
 development of, 435-446
 developmental stages of, 436
 immature, negative selection of, 439
 maturation of, 436, 439-440
 overview of, 435-436
 stage progression, regulation of, 438-439
 stem cell commitment of, 436-437
- B-cell chronic lymphocytic leukemia
 abnormal autoreactive B cell and, 36-38
 autoimmune phenomena in, 38
 biological correlates in, 8-9
 caspase expression in, 15-16
 clinical correlates in, 8-9
 cytogenetic alterations associated with, 12
 future research direction in, 32
 hypogammaglobulinemia in, 37-38
 immune cell function impairments in, 27-32
 incidence of, 27
 malignant B cells in, 27-29
 mantle cell lymphoma v, 9
 non-malignant B cells in, 29
 peripheral blood involvement in, 7
 primary immunodeficiency in, 27-32
 T-cell interaction with B cells in, 31
- B-cell development, lymphocyte survival regulation during, 443-444
- B-cell malignancy, autoreactive repertoire and, 36
- B-cell non-Hodgkin's lymphoma, molecular genetics of, 450-455
- Bacillus Calmette-Guerin, 640
- Baculovirus, as gene transfer vector, 665
- BAX 57, 453
- BAX protein, apoptosis dysregulation and, 14-15
- bcl-1 gene, 451, 452
 translocations on, 13
- bcl-2, 452-453
 apoptosis dysregulation and, 14-15
 in chronic lymphocytic leukemia, 51
 as prognostic factor, 45
 translocations on, 12-13
- bcl-3, 440, 455
- bcl-5, 440
- bcl-6, 454-455
- Benign monoclonal B-cell lymphocytosis, 43
- BEP regimen, for malignant ovarian germ cell tumors, 239
- Beta-carotene, in oral mucositis, 543
- Beta2-microglobulin, in chronic lymphocytic leukemia, 49
- Binet staging system, 43, 44
 in chronic lymphocytic leukemia, 113
- Biological markers, in germ cell tumors, 183
- Biological therapy, in ovarian cancer, 381-396
- Bispecific antibodies, 391, 685
- Bispecific costimulatory molecule, coupling of, 685-686
- Bleomycin
 alopecia induced by, 563
 in combination chemotherapy, 188
 emesis risk of, 578
 in germ cell tumor therapy, 188-190
 for malignant ovarian germ cell tumors, 239
 for poor-prognosis germ cell tumor, 197
 for stage I nonseminomatous germ cell tumor, 150-151, 157
 trials of, for good-risk germ cell tumors, 189
- Bleomycin, carboplatin, etoposide regimen, in stage I nonseminomatous germ cell tumor, 157-158
- Bleomycin, doxorubicin, vinblastine, dacarbazine regimen, in HD, 477-478
- Bleomycin, methotrexate, calcium folinic acid, doxorubicin, cyclophosphamide, vincristine, dexamethasone regimen, in NHL, 487-489
- Bleomycin, methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone regimen
 in NHL, 487-489
 oral mucositis due to, 541
- BNP7787, 591-592
 antitumor efficacy of, 594-596
 emesis induced by, 593
 for cisplatin-induced nephrotoxicity, 592-594
 mesna v, 596-597
 relative toxicity of, 597
 toxicity of, 594-596
- Bone marrow
 in chronic lymphocytic leukemia, 46-47
 diffuse pattern of, as prognostic factor, 45
 lymphocytes in, as prognostic factor, 45
- Bone marrow transplantation
 allogeneic, 62
 autologous, 215, 62
 in chronic lymphocytic leukemia, 113-114, 60-64
 with high-dose chemotherapy, 573
 purging in, 62-63
 stem cell source in, 60-62
- Borderline tumor(s)
 hormone replacement therapy and, 378
 mucinous, 374

- Borderline tumor(s) (*Continued*)
 non-serous-mucinous, 374
 of ovary, 372-380
 postoperative therapy of, 377-378
 prognostic factors in, 374-377
 serous, 373-374
 staging of, 377
 surgery for, 377
- BRCA1 gene, 260-261, 273
 germline mutation locations in, 269
 in ovarian cancer, 311
- BRCA2 gene, 273
 mutations in, 270-273
- Bryostatins, in chronic lymphocytic leukemia, 70
- BSAP, defined, 439
- Burkitt's lymphoma, 453, 454
 description of, 463-464
 Epstein-Barr virus and, 461-462
- Busulfan
 alopecia induced by, 563
 emesis risk of, 578
 oral mucositis due to, 541
- Buthionine sulfoximine, 383
- c-erbB2, ovarian cancer and, 381-383
- c-fms, ovarian cancer and, 382
- c-Kit protooncogene, 141
- CA125, 310-311
 increased, 317-318
 premenopausal conditions associated with, 322-323
- Calcitriol, in hair loss, 567-568
- Calcium, as prognostic factor, 45
- Calcium folinic acid, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone regimen, in NHL, 487-489
- Calcium folinic acid, prednisone, methotrexate, doxorubicin, cyclophosphamide, etoposide regimen, in NHL, 487-489
- Calvert formula, 352
- Camptothecin 1-H, in chronic lymphocytic leukemia, 70
- Cancer
 anemia associated with, 571
 in females, 316
 in situ, in germ cell cancer, 229
 staging in, and survival, 316
- Cancer screening
 cost of, 323
 design for, 320, 322
 in ovarian cancer, 315-325
 populations targeted for, 321-323
- Cancer vaccine
 chemotherapy v, 612
 clinical trials of, 609
 cytokine gene-transduced, basic research on, 667-672
 experimental basis for, 606-607
 revival of, 605-610
- Cancer-associated anemia, definition of, 571
- CancerVax, see Polyvalent melanoma vaccine
- Candida albicans*, in oral cavity infections, 540
- Capsaicin, in mucositis therapy, 546
- Carboplatin
 alopecia induced by, 563
 area-under-the-curve and, 344
 cisplatin v, for good-risk germ cell tumors, 190
 in combination chemotherapy, for germ cell tumors, 188
 emesis risk of, 578
 trials of, for good-risk germ cell tumors, 189
- Carboplatin, etoposide, bleomycin regimen, for stage I nonseminomatous germ cell tumor, 157-158
- Carboplatin, etoposide, cyclophosphamide regimen, for germ cell tumors, 219-220
- Carboplatin, etoposide, ifosfamide regimen, for germ cell tumors, 217-219
- Carboplatin, etoposide regimen, for germ cell tumors, 216-217
- Carboplatin, paclitaxel regimen, randomized trials of, 344
- Cardiac toxicity
 of anthracyclines, 525-537
 in children, 526-527
 of doxorubicin, 526
 of doxorubicin, paclitaxel regimen, 527
 of epirubicin, paclitaxel regimen, 527
 measurement of, 528-529
 of mediastinal irradiation, 166
 reduction of, 529
- Cardiomyopathy
 chronic, 525-526
 late-onset, 526
 therapy for, 534
- Cardiotoxicity, angiotensin-converting enzyme inhibitors and, 534
- Carmustine
 alopecia induced by, 563
 emesis risk of, 578
- Caspase, expression of, in B-cell chronic lymphocytic leukemia, 15-16
- Caspase-3, 16
- CCND1, 452
- CCND2, in germ cell tumors, 142
- CD4+ T helper lymphocyte, 385-386
- CD5, 29
 B-cell neoplasms with, 8
 coexpression of, 8
- CD10, 11
 B-cell neoplasms with, 8
- CD103, 8
- CD11c, 8
- CD19, 29, 440
- CD20, 47
 B-cell neoplasms with, 8
- CD23
 B-cell neoplasms with, 8
 soluble, 47-48
- CD25, 8
- CD40 ligand, 443-444
- CD45RO, 29
- CD4, 15
- Cell death, programmed, in B-cell chronic lymphocytic leukemia, 16
- Cell death protease, 15
- Cell-mediated immunity, in chronic lymphocytic leukemia, 100
- Central nervous system, germ cell tumor of, 243-250

- Chamomile, in oral mucositis, 545
- Chemokine, 683
- Chemosensitivity, intraperitoneal chemotherapy and, 356-357
- Chemotherapeutic agent(s)
- altered target of, 293
 - altered transport of, 291-292
 - inactivation of, 292-293
 - increased damage tolerance and, 294-295
 - increased DNA repair activity and, 294
 - sequestration of, 293-294
- Chemotherapy
- adjuvant, in ovarian cancer, 239
 - in advanced ovarian cancer, 340-348
 - bacterial infection following, 102
 - cancer vaccine v, 612
 - commonly used regimens of, in ovarian cancer, 239
 - complications of, for seminoma, 166
 - consolidation, 505-506
 - effect of, on spermatogenesis, 227-228
 - future directions in, 346-347
 - in germ cell tumors, 213
 - in good-risk germ cell tumors, 186-188
 - high-dose, see High-dose chemotherapy
 - induction, in ovarian cancer, 240
 - intraperitoneal, see Intraperitoneal chemotherapy
 - with lymphadenectomy, in stage II nonseminoma, 157
 - molecular, 399
 - multiple-cycle, as first-line therapy, 351-354
 - multiple-cycle high-dose, 349-355
 - neutropenia following, 552
 - new, 344-346
 - oral mucositis following, 538-551
 - in ovarian cancer, 238-241
 - regimens of, for good-risk germ cell tumors, 190
 - salvage, 504-505
 - issues in, for germ cell tumors, 210-211
 - salvage combination, 211-212
 - second-line, 344-346
 - in stage I nonseminomatous germ cell tumor, 150-151
 - in stage I testicular seminoma, 163
 - in stage II testicular seminoma, 164
 - teratogenicity of, 230
 - testicular function following, 229
 - toxicity of, prevention of, 521
- Chemotherapy-associated anemia
- clinical studies of, 571-574
 - cytokine combination therapy for, 573
 - epoetin alfa in, 571-576
 - nonrandomized trials in, 572
 - placebo-controlled trials of, 572, 573
- Children, chemotherapy-induced cardiac toxicity in, 526-527
- Chlorambucil
- alopecia induced by, 563
 - emesis risk of, 578
- Chlorhexidine gluconate, in oral mucositis, 544
- Chlorodeoxyadenosine, infection associated with, 103-104
- CHOP regimen, in NHL, 488
- Choriocarcinoma, 133
- Chromic phosphate
- intraperitoneal, 367-368
 - in ovarian cancer, 361-362
- Chromic phosphate (*Continued*)
- radioactive intraperitoneal, 361-364
 - randomized trials of, 361
- Chromosome(s)
- abnormalities of, nonrandom association between, 21-23
 - in chronic lymphocytic leukemia, 23-24
 - rearrangement in, genetic consequences of, 447-448
- Chromosome 3, 267
- Chromosome 5, abnormalities of, in germ cell tumors, 136-137
- Chromosome 6, 21
- Chromosome 8, 267
- Chromosome 12, in testis cancer, 134-135
- Chromosome 12p, in germ cell tumors, 142
- Chromosome 12q
- abnormalities of, in germ cell tumors, 136
 - deletions at, characterization of, 137
- Chromosome 17, 270, 271
- Chromosome 20, 267
- Chronic lymphocytic leukemia
- alkylator therapy in, 68
 - anthracyclines in, 67-68
 - autoimmune derangements in, 80-82
 - autoimmune disease and, 80-97
 - autoimmune phenomena in, 34-41
 - bacterial infection in, 102
 - Binet staging of, 113, 43
 - bone marrow involvement pattern in, 110-111
 - bone marrow transplantation in, 60-64, 113-114
 - bryostatin in, 70
 - campath 1-H in, 70
 - causes of death in, 111
 - cell-mediated immunity in, 100
 - chromosome abnormalities in, 19-21
 - chromosomes in, 23-24
 - clinical findings in, 108
 - clinical prognostic factors in, 44-47
 - complement activity in, 100
 - conventional treatment of, 112
 - cytogenetics in, 19-26, 49-52
 - diagnosis of, 42-44
 - failed programmed cell death and, 11-12
 - flavopiridol in, 70
 - fludarabine therapy of, 112-113
 - fungal infection in, 102
 - genetics of, 12-14
 - hypogammaglobulinemia in, 98-99
 - immunization in, 101
 - immunophenotype in, 47-48
 - incidence of, 4
 - infectious complications of, 98-106
 - initiating treatment in, 66
 - intravenous immunoglobulin in, 99-100
 - introduction to, 4-5
 - laboratory findings in, 108, 109
 - laboratory prognostic factors in, 44-47
 - lymphocyte doubling time in, 44-46, 109-110
 - lymphocyte subsets in, 48
 - molecular biology of, 11-18, 49-52
 - monitoring guidelines in, 53
 - monoclonal antibodies in, 68
 - mucosal immunity in, 101

- Chronic lymphocytic leukemia (*Continued*)
 multidrug resistance gene in, 52-53
 multiple myeloma arising in, 123
 natural history of, 111
 new drug screening for, 67
 nonprotocol treatment options in, 65-67
 nursing care in, 75-79
 presenting features of, 107-108
 prognostic factors in, 108-109, 111
 purine analogs in, 67-68, 68
 Rai staging of, 43, 113
 restricted trisomy combinations in, 22
 in Richter's transformation, 117-125
 smoldering, 43-44, 111
 specific chromosome abnormalities in, 20
 staging of, 42-44, 109
 survival in, 110
 theophylline in, 68-69
 topoisomerase I inhibitors in, 69-70
 treatment of, 111-112
 UCN-01 in, 69
 viral infection in, 102-103
 white cell count in, 100-101
 in young patients, 107-116
- Chronic lymphoid leukemia, flow cytometry in, 6-10
- Cisplatin
 alopecia induced by, 563
 antitumor versus toxic effects of, 586-587
 carboplatin v, for good-risk germ cell tumors, 190
 in combination chemotherapy, 121-122, 188
 controversies associated with, 343-344
 emesis risk of, 578
 for germ cell tumors, 188
 intraperitoneal, in ovarian cancer, 359
 for malignant ovarian germ cell tumors, 239
 nephrotoxicity of, BNP7787 for, 592-594
 in ovarian cancer, 341-343
 pharmacologic chemistry of, 584-586
 for poor-prognosis germ cell tumor, 197
 randomized trials of, 342
 for stage I nonseminomatous germ cell tumor, 150-151, 157
 toxicity of, amifostine reduction of, 522-524
- Cisplatin, amifostine regimen, early experience with, 522
- Cisplatin, cyclophosphamide regimen, 341
- Cisplatin, cyclophosphamide, amifostine regimen, phase III trial of, 522-523
- Clonal deletion theory, 34-35
- CNS lymphoma
 diagnosis of, 496
 pathogenesis of, 496
 primary, 496-498
 treatment of, 496-497
- Cocaine, in mucositis therapy, 546
- Cockcroft-Gault equation, 352
- Colony-stimulating factor(s)
 dosing of, 558
 efficacy of, 559
 in leukemia, 556-557
 in ovarian cancer, 349-355
 phase III trials of, 556
 in reducing chemotherapeutic toxicity, 557-558
- Colony-stimulating factor(s) (*Continued*)
 scheduling of, 558
 secondary use of, 555
 therapeutic use of, 555-556
- Combination chemotherapy
 anthracycline, toxicities of, 527
 emetic risk of, 578
- Complement activity, in chronic lymphocytic leukemia, 100
- Complement system, in chronic lymphocytic leukemia, 48
- Computed tomography
 following melacine, 627-629
 in ovarian cancer, 319
- Consolidation therapy, multiple-cycle chemotherapy as, 350-351
- Corticosteroids
 for chemotherapy-induced emesis, 580
 in oral mucositis, 544
- Counseling
 following chemotherapy, 231
 following orchiectomy, 231
 following radiation therapy, 231
 prior to orchiectomy, 230
- Cryotherapy, in oral mucositis, 542
- Cryptorchid testis, 168
- CT, see Computed tomography
- Cyclin-D1, 13, 452
- Cyclophosphamide, 640
 alopecia induced by, 563
 in chronic lymphocytic leukemia, 66
 in combination chemotherapy, 121-122
 emesis risk of, 578
 for germ cell tumors, 188
 oral mucositis due to, 541
- Cyclophosphamide, carboplatin, etoposide regimen, for germ cell tumors, 219-220
- Cyclophosphamide, cisplatin regimen, in ovarian cancer, 341
- Cyclophosphamide, cisplatin, amifostine regimen, phase III trial of, 522-523
- Cyclophosphamide, doxorubicin, vincristine, prednisone regimen, in NHL, 487-489
- Cyclophosphamide, methotrexate, calcium folinic acid, bleomycin, doxorubicin, vincristine, dexamethasone regimen, in NHL, 487-489
- Cyclophosphamide, methotrexate, doxorubicin, vincristine, prednisone, bleomycin regimen, in NHL, 487-489
- Cyclophosphamide, paclitaxel, G-CSF regimen, in ovarian cancer, 352
- Cyclophosphamide, prednisone, methotrexate, calcium folinic acid, doxorubicin, etoposide regimen, in NHL, 487-489
- Cyclophosphamide, vincristine, dactinomycin regimen, for malignant ovarian germ cell tumors, 239
- Cyclosporine A
 in autoimmune hemolytic anemia, 87, 91
 in hair loss, 567
- Cytarabine
 alopecia induced by, 563
 emesis risk of, 578
- Cytogenetic(s)
 abnormalities of, as prognostic factor, 45
 in chronic lymphocytic leukemia, 49-52

- Cytogenetic(s) (*Continued*)
 prognostic value of, 24
 of testis cancer, 134-135
- Cytokine(s), 497
 in chronic lymphocytic leukemia, 49
 in oral mucositis, 543
 production of, and T lymphocytes, 649
 tumor vaccines and, 609
- Cytoreductive surgery
 aggressive surgical procedures for, 331
 clinical benefits of, 328-330
 interval debulking, 332-333
 in ovarian cancer, 328-333
 in ovarian germ cell tumors, 408
 primary, 328
 theoretical benefits of, 328
- Cytosine arabinoside
 in combination chemotherapy, 121-122
 oral mucositis due to, 541
- Cytotoxic T lymphocyte, immune response and, 632-63
- D gene, 13
- Dacarbazine
 alopecia induced by, 563
 emesis risk of, 578
- Dacarbazine, doxorubicin, bleomycin, vinblastine regimen, in HD, 477-478
- Dactinomycin, in combination chemotherapy, for germ cell tumors, 188
- Dactinomycin, vincristine, cyclophosphamide regimen, for malignant ovarian germ cell tumors, 239
- Danazol, in autoimmune hemolytic anemia, 87, 91
- Daunorubicin, 529
 alopecia induced by, 563
 emesis risk of, 578
 oral mucositis due to, 541
- DBM gene, in chronic lymphocytic leukemia, 50
- DCC gene, in germ cell tumors, 139
- Death, in chronic lymphocytic leukemia, 76
- Delayed-type hypersensitivity, 636
 as antitumor immunity measure, 651
- Deleted in B cell malignancy gene, in chronic lymphocytic leukemia, 50
- Dental care, in oral mucositis, 544
- Deoxycoformycin, infection associated with, 103-104
- Deoxythymidine kinase, as prognostic factor, 45
- Dependence, in chronic lymphocytic leukemia, 77
- Detox, 623, 640
- Dexamethasone, 581
 dosing of, 579
- Dexamethasone, methotrexate, calcium folinic acid, bleomycin, doxorubicin, cyclophosphamide, vincristine regimen, in NHL, 487-489
- Dexrozoaxane, 525
 adult studies of, 532
 cardiotoxicity and, 531
 chemical structure of, 530
 proposed mechanism of, 531
- Dexrozoaxane, doxorubicin regimen, 531-534
- Dexrozoaxane, epirubicin regimen, adult studies of, 532
- Diet
 in mucositis therapy, 545
 ovarian cancer and, 259
- Diethyldithiocarbamate, 590
- Diffuse aggressive lymphoma, 487-489
- Diffuse large B-cell lymphoma, 426-427
- Diffuse large cell lymphoma, 426
- Dinitrophenyl, 647
- Dinitrophenyl-modified vaccine
 administration of, 648
 antitumor responses following, 649
 autologous, preparation of, 648
 in ovarian cancer, 651-652
 postsurgical adjuvant studies with, 650-651
 toxicity of, 648
- Dinoprostone, in oral mucositis, 544
- Disability, in chronic lymphocytic leukemia, 77
- Disfigurement, in chronic lymphocytic leukemia, 77
- Disruption, in chronic lymphocytic leukemia, 77
- DNA mismatch repair, in germ cell tumors, 141
- Docetaxel, 345-346
 alopecia induced by, 563
 emesis risk of, 578
 oral mucositis due to, 541
- Dolasetron, dosing of, 579
- DOXIL, 529-530
- Doxorubicin
 adult studies of, 532
 alopecia induced by, 563
 cardiac toxicity of, 526, 531
 cumulative doses of, cardiac toxicity and, 533
 emesis risk of, 578
 for chronic lymphocytic leukemia, 66
 liposomal, 345-346, 529-530
 oral mucositis due to, 541
- Doxorubicin, bleomycin, vinblastine, dacarbazine regimen, in HD, 477-478
- Doxorubicin, cyclophosphamide, vincristine, prednisolone regimen, in NHL, 487-489
- Doxorubicin, dexrozoaxane regimen, 531-534
- Doxorubicin, methotrexate, calcium folinic acid, bleomycin, cyclophosphamide, vincristine, dexamethasone regimen, in NHL, 487-489
- Doxorubicin, methotrexate, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in NHL, 487-489
- Doxorubicin, paclitaxel regimen, cardiac toxicities of, 527
- Doxorubicin, prednisone, methotrexate, calcium folinic acid, cyclophosphamide, etoposide regimen, in NHL, 487-489
- DR protein, 467
- Drug resistance, 311-312
 in ovarian cancer, 290-295
- Drug screening, for chronic lymphocytic leukemia, 67
- Drug(s), chemotherapeutic, see Chemotherapeutic agent(s)
- Dysgerminoma, 410-411
 therapy for, 239, 240
- E-cadherin, ovarian cancer and, 382
- Early B-cell factor, 437
- Echocardiography, two-dimensional, in cardiac toxicity, 528
- Embryonal carcinoma, 133

- Emesis
 chemotherapy-induced, 577-583
 delayed, 581-582
 patient prognostic factors for, 578
 risk of, by chemotherapeutic agent, 577-578
- Endometrial cancer, early onset of, 274
- England, most common female cancers in, 316
- Env gene, 467
- Epidermal growth factor
 in hair loss, 567
 in oral mucositis, 543-544
 ovarian cancer and, 381
- Epirubicin, 529
 emesis risk of, 578
 oral mucositis due to, 541
- Epirubicin, dextrozoaxane regimen, adult studies of, 532
- Epirubicin, paclitaxel regimen, cardiac toxicities of, 527
- Epoetin alfa
 in chemotherapy-associated anemia, 571-576
 cost-effectiveness of, 574-575
 dosing of, 574
 predictors of response to, 574
 with radiation therapy, 572-573
 quality of life following, 573-574
 safety of, 574
 uses of, 572
- Epstein-Barr virus, 449
 biology of, 462-463
 Burkitt's lymphoma and, 461-462
 malignancies associated with, 464
- ErbB1, 381-383
- Esorubicin, 529
- Ethylol, 587
 relative toxicity of, 597
- Etoposide, 186-187
 alopecia induced by, 563
 in combination chemotherapy, for germ cell tumors, 188
 emesis risk of, 578
 for germ cell tumors, 213
 for malignant ovarian germ cell tumors, 239
 oral, 345-346
 for poor-prognosis germ cell tumor, 197
 for stage I nonseminomatous germ cell tumor, 150-151, 157
- Etoposide, carboplatin regimen, as germ cell tumor salvage therapy, 216-217
- Etoposide, carboplatin, bleomycin regimen, for stage I nonseminomatous germ cell tumor, 157-158
- Etoposide, cyclophosphamide regimen, for germ cell tumors, 219-220
- Etoposide, ifosfamide regimen, for germ cell tumors, 217-219
- Etoposide, prednisone, methotrexate, calcium folinic acid, doxorubicin, cyclophosphamide regimen, in NHL, 487-489
- Fas, in chronic lymphocytic leukemia, 51-52
- Fatigue, in chronic lymphocytic leukemia, 78
- Fertility
 cancer therapy and, 228-229
 following seminoma therapy, 166
- Fibroblast growth factor, in hair loss, 567
- Flavopiridol, in chronic lymphocytic leukemia, 70
- Flow cytometry, in chronic lymphoid leukemias, 6-10
- Flower cell, 468
- Fludarabine
 in chronic lymphocytic leukemia, 66-67, 112-113
 in combination chemotherapy, 121-122
 infection associated with, 103-104
- Fluorouracil
 alopecia induced by, 563
 oral mucositis due to, 541
- FMC7, B-cell neoplasms with, 8
- Folinic acid, in oral mucositis, 542
- Follicle center cell lymphoma, peripheral blood involvement in, 7
- Follicular lymphoma, 425-426
 remission duration in, 485
- Follicular NHL, 483-485
- Fox Chase Cancer Center Protocol 96-100
 schema for, 354
- Fucosyl GM1, 637-639, 642
- G-protein-coupled receptor, 470
- Gag gene, 467
- Ganglioside, expression of, at cancer cell surface, 637-639
- Ganglioside vaccine(s)
 definition of, 636
 future directions for, 642-643
- GD1 ganglioside, immunogenicity of, 641-642
- GD3 ganglioside, immunogenicity of, 641-642
- GD3 lactone, 642
- Gemcitabine
 emesis risk of, 578
 in ovarian cancer, 345-346
- Gender, as prognostic factor, in chronic lymphocytic leukemia, 44
- Gene amplification, 448
- Gene therapy
 ex vivo, 661-676
 future directions in, 402-403
 in ovarian cancer, 397-406
 strategies for, 399
- Gene transfer vector, 665
- Genetic imprinting, in germ cell tumors, 142
- Genetics, ovarian cancer and, 265-280
- Germ Cell Consensus Classification of Intermediate and Poor Prognosis Groups, 196
- Germ cell tumor(s)
 biological marker in, 183
 bleomycin therapy for, 188-190
 of central nervous system, 243-250
 chemotherapy treatment schemes for, 188
 clinical characteristics of, 243
 conventional-dose salvage treatment in, 180-181
 cytogenetics of, 134-135
 dose-intensive therapy for, 215-223
 embryology of, 243
 etoposide, carboplatin regimen for, 216-217
 etoposide, carboplatin, cyclophosphamide regimen for, 219-220
 etoposide, ifosfamide regimen for, 217-219
 first-line therapy for, 220-221
 frequent nonrandom chromosomal abnormalities in, 135

- Germ cell tumor(s) (*Continued*)
 good-risk, therapy for, 186-193
 good-risk disease identification in, 187-188
 high-dose chemotherapy trials for, 218
 high-dose salvage treatment in, 181-182
 histology of, 133
 imprinting in, 142
 Indiana University Classification system for, 187
 intracranial, surgery for, 244-245
 introduction to, 131-132
 late relapse in, 213-214
 in males, genetic perspective of, 133-144
 metastatic, prognostic factors in, 174-185
 microsatellite instability in, 141
 mixed, 248
 molecular genetic studies of, 135-142
 nongerminomatous, 248
 ovarian, 235-242, 407-413
 pathology of, 243-244
 poor-prognosis, *see* Poor-prognosis germ cell tumor(s)
 post-treatment marker decline in, 182-183
 prognostic variables in, 181
 radiation therapy for, 245
 recurrent, of central nervous system, 210-214, 247-248
 retroperitoneal metastasis staging in, 204
 salvage treatment in, prognostic factors for, 180-182
 stage I, 203-205
 stage II, 205
 stage IIC-III, 205-207
 surgery in, 203-209
 therapy for, late effects of, 245-246
 tumor markers in, 244
- Germinal center, formation of, 440-441
- Germinoma, pure, 248
- Glutamine, in oral mucositis, 543
- Glutathione, 383
- Glycogen synthase kinase 3, 266
- GM2, structure of, 637
- GM2 ganglioside vaccine, immunogenicity of, 639-641
- GM2-keyhole limpet hemocyanin conjugate vaccine, plus QS21, 641
- Gold gene gun, mechanical administration colloidal, as gene transfer vector, 665
- Gonadal function
 biological aspects of, in testicular cancer, 224-225
 cancer therapy impact on, 226-229
 following orchiectomy, 226
 impaired, causes of, 225-226
 prior to orchiectomy, in testicular cancer, 225
 in testicular cancer, 224-233
- Gonadal toxicity
 prediction of, 229-230
 prevention of, 230
- Graft versus host disease, 63
- Graft versus leukemia effect, 63
- Granisetron, dosing of, 579
- Granulocyte colony-stimulating factor, 285
 biologic effects of, 552-553
 in oral mucositis, 543
 phase III trials of, 556
 primary use of, 553-554
- Granulocyte colony-stimulating factor, paclitaxel, cyclophosphamide regimen, in ovarian cancer, 352
- Granulocyte-macrophage colony-stimulating factor
 biologic effects of, 552-553
 in oral mucositis, 543
 phase III trials of, 556
 primary use of, 554-555
- Growth factor gene, in germ cell tumors, 141-142
- Guidelines, in chronic lymphocytic leukemia monitoring, 53
- Gynecologic Oncology Group 9501, schema for, 353
- H19, in germ cell tumors, 142
- Hair dye, ovarian cancer and, 259
- Hair growth, physiology of, 562
- Hair loss
 in vitro studies of, 566-568
 physiology of, 562
 prevention of, 563-566
 psychology of, 563
- Hairy cell leukemia, 7-8
 peripheral blood involvement in, 7
 properties of, 9
- Hapten, definition of, 647
- Hapten modification, definition of, 647
- Hapten-modified vaccine, autologous, in cancer therapy, 646-653
- HD, *see* Hodgkin's disease
- Health Insurance Portability and Accountability Act, 77
- Heat-shock protein, 608
- Heat-shock protein-based anticancer immunotherapy, 654-660
- Heat-shock protein-peptide complex
 antigenic characteristics of, 655-656
 efficiency of, 658
 ethical considerations related to, 659
 immune response mediated by, 656
 manufacturing of, 658-659
 preparation of, 657
 research regarding, 658
 safety of, 657-658
 tumor-derived, manufacture of, 656-657
- Hemagglutinin-neuraminidase, of virus, 686
- Hematopoietic growth factor
 biologic effects of, 552
 in chemotherapeutic toxicity, 552-561
 clinical data for, 553
- Hepatomegaly, as prognostic factor, 45
- HER2-neu, ovarian cancer and, 381-383
- Hereditary breast-ovarian cancer, 270-273
- Hereditary nonpolyposis colorectal cancer, ovarian cancer in, 273
- Hereditary ovarian cancer, 270-273
 pathology of, 273-275
 prophylactic surgery in, 276-277
 risk for, patient management at, 275
 screening for, 276
 survival following, 273-275
- Herpes simplex virus
 as gene transfer vector, 665
 in oral cavity infection, 539-540
- Heterozygosity, loss of, in germ cell tumors, 135-138
- Hexamethylmelamine, alopecia induced by, 563

- High-dose chemotherapy, 503-517
 bone marrow transplantation plus, 573
 with hematopoietic stem cell support, 199
 prognostic factors in, 221
 in relapsed NHL, 507
 trials of, 218
- HIV infection, lymphomas and, 492-502
- Hodgkin's disease, 429-430, 497
 allogeneic transplantation in, 511
 chemotherapy in, 477-478
 classical, 430
 doxorubicin, bleomycin, vinblastine, dacarbazine regimen in, 477-478
 early-stage, management of, 476-482
 Epstein-Barr virus and, 466
 high-dose chemotherapy in, 503
 immunophenotypic features of, 429
 mechlorethamine, vincristine, procarbazine, prednisone regimen in, 476-478
 radiation therapy in, 477
 as Richter's syndrome variant, 122-123
 stem cell transplantation in, 511
 treatment complications in, 479-481
- Hormone replacement therapy, borderline tumors and, 378
- Hormones, ovarian cancer and, 257-258
- HTLV-1, biology of, 467-468
- Human chorionic gonadotropin, 210-211
 beta-, in testicular seminoma, 168
 posttreatment, in germ cell tumors, 182-183
- Human herpesvirus-8, 449, 469-470
 biology of, 470-471
 lymphoproliferative disorders and, 471
- Human T-cell lymphotropic virus I, 449
- Humoral immune response, refinement of, 440-441
- Hydroxypropyl cellulose films, in mucositis therapy, 546
- Hydroxyurea
 alopecia induced by, 563
 emesis risk of, 578
 oral mucositis due to, 541
- Hypersensitivity, delayed-type, 636
- Hypogammaglobulinemia, 98-99
 in chronic lymphocytic leukemia, 37-38
- Hysterectomy, ovarian cancer and, 258
- Idarubicin, 529
 emesis risk of, 578
- Ifosfamide
 alopecia induced by, 563
 emesis risk of, 578
- Ifosfamide, carboplatin, etoposide regimen, for germ cell tumors, 217-219
- IGF2, in germ cell tumors, 142
- Ikaros, 436-437
- Immune thin-layer chromatography, 637-638
- Immunity
 cellular, impairments in, 29-32
 T-cell-mediated, 29-30
- Immunization
 active, against cancer cells, 697-706
 in chronic lymphocytic leukemia, 101
 perspectives for, 703
- Immunization (*Continued*)
 requirements for, 698
 with virus-modified tumor cells, 677-696
- Immunoabsorption, in autoimmune hemolytic anemia, 87, 91
- Immunoblastic B-cell lymphoma, 426-427
- Immunocompromised patient, lymphomas in, 492-502
- Immunoglobulin, in chronic lymphocytic leukemia, 48
- Immunoglobulin gene, somatic hypermutation of, 442
- Immunohistology, 638
- Immunology, tricks with, in cancer therapy, 646-647
- Immunomodulation, 701-703
- Immunophenotypes, in chronic lymphocytic leukemia, 47-48
- Immunopotentiating drug, tumor vaccines and, 609
- Immunopotential, 401
- Immunoprophylaxis, definition of, 606-607
- Immunostimulatory gene transfer, 664
- Immunosuppression
 in chronic lymphocytic leukemia, 77
 Richter's syndrome and, 121
 testicular seminoma and, 168-169
- Immunotherapy
 active specific, 623-635
 adoptive cellular, 386-387
 in humans, 699-700
 hurdles to overcome with, 700-701
 in mice, 698-699
 principles of, 605-606
 with heat-shock protein-based anticancer immunotherapy, 654-660
- Immunotherapy system, cancer vaccine in, 607
- Immunotoxins, 390-391
- Imprinting, genetic, in germ cell tumors, 142
- ImuVert, 567
- Indiana University Classification System, for germ cell tumors, 187
- Infection, 98-106
 in chronic lymphocytic leukemia, 78-79
- Interferon, in indolent NHL, 484
- Interferon alpha, 386, 683
 following melacine, 626-630
- Interferon alpha, melacine regimen, clinical trials of, 630
- Interferon beta, 683
- Interferon gamma, 386
- Interleukin-1, 683
 in oral mucositis, 543
- Interleukin-2, 386
 ovarian cancer and, 382
- Interleukin-4, 382
- Interleukin-6, 384, 497-498, 683
 ovarian cancer and, 382
- Interleukin-10, 382
- Interleukin-12, 382
- International Federation for Gynecology and Obstetrics Staging System for Ovarian Cancer, 237
- International Germ Cell Cancer Collaborative Group Classification, 179-180
- International Germ Cell Cancer Collaborative Group Consensus Prognostic Classification, 188
- International Germ Cell Consensus Classification, in poor-prognosis germ cell tumors, 195-196

- International Lymphoma Study Group, classification of, 422-423
- Intracellular adhesion molecule 1, soluble, 48-49
- Intraperitoneal chemotherapy
factors limiting utility of, 357
favorable clinical settings for, 359
future directions in, 359
initial, 358
in ovarian cancer, 356-360
role of, 358-359
salvage, survival following, 357-358
- Intravenous immunoglobulin
in autoimmune hemolytic anemia, 86, 91
in chronic lymphocytic leukemia, 99-100
- IP-10, 683
- Irinotecan, emesis risk of, 578
- Isotype switching, 441-442
- J gene, 13
- Karyotype, partial, of trypan-Giemsa-banded metaphase cell, 453
- Keyhole limpet hemocyanin, 640
- Ki-67, as prognostic factor, 45
- Kiel classification, 421-423
- KIT expression, in germ cell tumors, 141-142
- L-asparaginase, alopecia induced by, 563
- Laparoscopy, second-look, 332
- Laparotomy
in HD staging, 476
in ovarian cancer management, 327
in ovarian germ cell tumors, 411
second-look, 308, 330-332
staging with, in ovarian cancer, 326-327
- Large granular lymphoproliferative disorder, 7
- Laser, in mucositis therapy, 546
- Leucovorin, in oral mucositis, 542
- Leukemia
chronic lymphocytic, see Chronic lymphocytic leukemia
colony-stimulating factors in, 556-557
- Leydig's cell, function of, 227, 228-229
- Lidocaine, in mucositis therapy, 546
- Liposome, as gene transfer vector, 665
- Liposome-entrapped monoclonal antibodies, in hair loss, 567
- Lomustine
alopecia induced by, 563
emesis risk of, 578
- Loss of heterozygosity
chromosomal areas exhibiting, 140
common regions of, 288
in germ cell tumors, 135-138
ovarian cancer and, 260, 269
- Lymphadenopathy, as prognostic factor, 45
- Lymphocyte(s)
malignant chronic lymphocytic leukemia B, 37
subsets of, in chronic lymphocytic leukemia, 48
- Lymphocyte doubling time, 44-47
- Lymphocytosis
benign monoclonal B-cell, 43
peripheral blood, 45
reactive v neoplastic, 6-7
- Lymphokine-activated killer cells, 385
- Lymphoma
AIDS-associated, 456-457
diffuse aggressive, 487-489
following bone marrow transplantation, 498-499
in immunocompromised patients, 492-502
of intermediate differentiation, 424
malignant, see Malignant lymphoma
MALT, 423
marginal zone, 423
monocytoid B-cell, 423
of mucosa-associated lymphoid tissue, 423, 486
pathogenesis of, 461-475
post-transplant, 457
- Lymphomagenesis, mechanisms of, 447-449
- Lymphoplasmacytoid lymphoma, 7
- Lymphotoxin-alpha, 440-441
- Lynch syndrome II, 273, 274
- Lysate vaccine
antigenic profile of, 625
composition of, 624-625
long-term clinical response with, 626
- Macrophage colony-stimulating factor, 285, 384
ovarian cancer and, 382
- MAGE antigen, 662
- MAGE protein, 608
- Magic Mouthwash, in mucositis therapy, 546
- Magnesium hydroxide, 546
- Magnetic resonance imaging, in ovarian cancer, 319
- Male sex, as prognostic factor, 45
- Malignant lymphoma
classification of, 421-434
establishing diagnosis of, 430
unique clinicopathologic presentations of, 427
- Malignant transformation, of ovarian surface epithelial cells, 289-290
- MALT lymphoma, 423
overall survival in, 486
- Mantle cell lymphoma, 13, 424-425
B-cell chronic lymphocytic leukemia v, 9
overall survival in, 486
peripheral blood involvement in, 7
- Marginal zone lymphoma, 423, 485-486
splenic, 423
- Mast cell growth factor, in germ cell tumors, 141-142
- MAX, 451
- MDM2 gene, 21
- Mechlorethamine, oral mucositis due to, 541
- Mechlorethamine, vincristine, procarbazine, prednisone regimen, in HD, 476-478
- Melacine
clinical trials with, 625-626
CT following, 627-629
frozen lysates regimen with, in stage II-III melanoma, 630-632
interferon-alpha following, 626-630
- Melacine, interferon-alpha regimen, clinical trials of, 630
- Melanoma
allogeneic lysate vaccine for, 623-635
stage II-III, 630-632
stage IV, 630

- Melanoma antigen, novel genes encoding, 633
- Melanoma Gene 50, 633
- Melanoma vaccine
- clinical trials of, 613-619
 - polyvalent, 613-617
 - principles of, 612-613
- Melanoma-associated antigen, tumor-associated antigens v, 615
- Melanoma-associated protein, 608
- Melphalan
- alopecia induced by, 563
 - emesis risk of, 578
 - in ovarian cancer, 361-362
- Memory cell, differentiation into, 442-443
- Mercaptopurine
- alopecia induced by, 563
 - oral mucositis due to, 541
- Mesna
- BNP7787 v, 596-597
 - relative toxicity of, 597
- Metastasis, inflammation responses in, 648-649
- Metastatic nonseminomatous germ cell tumor(s), 180
- historical models in, 177-179
 - prognostic factors in, 177
 - variables in, 178
- Metastatic seminoma
- historical models of, 174-175
 - International Germ Cell Cancer Collaborative Group classification and, 175
 - prognostic factors in, 174-185
 - variables in, outcome and, 175
- Methotrexate
- alopecia induced by, 563
 - emesis risk of, 578
 - oral mucositis due to, 541
- Methotrexate, calcium folinic acid, bleomycin, doxorubicin, cyclophosphamide, vincristine, dexamethasone regimen, in NHL, 487-489
- Methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, bleomycin regimen, in NHL, 487-489
- Methotrexate, prednisone, calcium folinic acid, doxorubicin, cyclophosphamide, etoposide regimen, in NHL, 487-489
- Methyl-glyoxal-bis guanyldiazide, 497
- Methylprednisolone, dosing of, 579
- Microsatellite instability, in male germ cell tumors, 141
- Minimal residual disease, monitoring of, 509
- Minoxidil, 566
- in hair loss, 567
- Mithromycin, oral mucositis due to, 541
- Mitomycin
- alopecia induced by, 563
 - emesis risk of, 578
 - oral mucositis due to, 541
- Mitoxantrone, 529
- alopecia induced by, 563
 - emesis risk of, 578
- Molecular biology, in chronic lymphocytic leukemia, 49-52
- Monoclonal antibody(ies)
- bispecific, 391
 - in chronic lymphocytic leukemia, 68
 - engineering, 388-389
- Monoclonal antibody(ies) (Continued)
- immunotoxins, 390-391
 - in ovarian cancer, 387-391
 - radioconjugates, 389-390
 - reagents, 387-388
 - representative, conjugates, 388
- Monoclonal B-cell lymphocytosis, benign, 43
- Monocytoid B-cell lymphoma, 423
- Monocytoid B-cell NHL, 485-486
- Monophosphoryl lipid, 640
- MOPP chemotherapy, in HD, 477
- Morphine, in mucositis therapy, 547
- Mouse double minute 2 amplification, 138-139
- Mouthwash, in mucositis therapy, 546
- MRI, see Magnetic resonance imaging
- Mucosa-associated lymphoid tissue lymphoma, 485-486
- Mucosal lymphocyte antigen, 7
- Mucositis, oral, see Oral mucositis
- MUGA radionuclide imaging, for cardiotoxicity, 528
- Multicentric Castleman's disease, 471
- Multidrug resistance, 401
- in ovarian cancer, 290-295
- Multidrug resistance gene
- in chronic lymphocytic leukemia, 52-53
 - as prognostic factor, 45
- Multimodal screening, in ovarian cancer, 319-320
- Multiple myeloma, in chronic lymphocytic leukemia, 123
- Mutation compensation, 400-401
- MYC, 450-451, 463-464
- Mycosis fungoides, peripheral blood involvement in, 7
- Myelomonocytic antigen, 48
- N-acetylcysteine, 567
- Natural autoantibody activity, 35-36
- Natural killer cell, 30-32
- in ovarian cancer, 385
- Natural killer cell lymphoma, 428-429
- Nephrotoxicity, cisplatin-induced, BNP7787 for, 592-594
- Neural cell adhesion molecule, 139
- Neurokinin receptors, 582
- Neutropenia, following chemotherapy, 552
- Newcastle disease virus
- autologous tumor vaccine-, production of, 678-680
 - for tumor therapy, 677-678
- NHL, see Non-Hodgkin's lymphoma
- Nitrogen mustard
- alopecia induced by, 563
 - emesis risk of, 578
- NK-1, 582
- NME gene, role of, in germ cell tumors, 140-141
- Nodular type of lymphocyte predominant Hodgkin's disease, 429-430
- Non-Hodgkin's lymphoma
- AIDS-related, 465-466
 - CHOP regimen in, 488
 - chromosomal abnormalities in, 447-460, 449
 - chromosomal markers of, 452
 - classification of, 421-423
 - classification systems in, 449
 - diagnosis of, 423-429
 - follicular, 483-485

Non-Hodgkin's Lymphoma (*Continued*)

- genetic markers of, 452
 - high-grade, 510
 - indolent, 508-510, 512
 - intermediate aggressive, 506-508
 - management of, 483-491
 - molecular genetics of, 447-460
 - partial karyotypes in, 453
 - salvage regimen in, 489
 - stem cell transplantation in, 511-512
 - T-cell, molecular genetics of, 456
 - unbalanced chromosomal abnormalities in, 451
- Nondysgerminoma, therapy for, 239-241
- Nonpulmonary visceral metastasis, 175
- Nonseminomatous germ cell tumor(s)
- carboplatin, etoposide, bleomycin regimen in, 157-158
 - cisplatin, etoposide, bleomycin regimen in, 150-151, 157
 - metastatic, see Metastatic nonseminomatous germ cell tumor(s)
 - overview of, 155, 158
 - primary chemotherapy in, 150-151
 - primary mediastinal, 197
 - prognostic factors in, 146-147, 157
 - retroperitoneal lymph node dissection in, 147-149
 - in Royal Marsden Hospital, 156-157
 - stage I, 154-155
 - stage I-II, orchidectomy in, 154-159
 - stage II, 155-156
 - surgery v surveillance in, 145-153
 - surveillance in, 149-150
 - surveillance studies in, 147
- Nuclear factor KB, 451
- Nucleotide diphosphate kinase, in germ cell tumors, 140
- Nursing care, in chronic lymphocytic leukemia, 75-79
- Nutrition, in chronic lymphocytic leukemia, 78

O-acetyl GD3 gangliosides, 642

- immunogenicity of, 641-642

Oncogene, dominantly acting, in germ cell tumors, 141-142

Oncogenic virus, 448-449

Ondansetron, dosing of, 579

Oral cavity, viral infections of, 539-540

Oral contraceptives, ovarian cancer and, 257, 258

Oral hygiene

- in mucositis therapy, 545
- in oral mucositis, 544

Oral mucositis

- chemotherapeutic agents associated with, 541
- dietary guidelines in, 545
- following chemotherapy, 538-551
- pathophysiology in, 538
- patient assessment in, 541-542
- patient-related risk factors in, 540-541
- prevention and therapy algorithm for, 539
- prevention of, 542-545
- Radiation Therapy Oncology Group grading of, 542
- treatment of, 545
- treatment-related risk factors in, 541
- World Health Organization grading of, 541
- xerostomia and, 541

Orchiectomy

- chemotherapy following, 154-159
- gonadal function following, 225
- gonadal function prior to, 225
- patient counseling following, 231
- patient counseling prior to, 230

Ovarian cancer

- adhesions in, 384-385
- advanced, 309, 340-348
- advanced-stage, 328-333
- allelic loss patterns in, 271
- analytic epidemiology of, 256-259
- angiogenesis in, 384-385
- biological therapy of, 381-396
- biology of, 281-304
- borderline tumors in, 307
- chemotherapy in, 238-241
- cisplatin, etoposide, bleomycin regimen in, 239
- cisplatin, vinblastine, bleomycin regimen in, 239
- colony-stimulating factors in, 349-355
- CT in, 319
- current research in, 261
- cyclophosphamide, cisplatin regimen in, 341
- cyclophosphamide, cisplatin, amifostine regimen in, 522-524
- cytoreductive surgery in, 328-333
- descriptive epidemiology of, 255-256
- design for screening in, 320, 322
- development of, concepts in, 282
- dietary factors and, 259
- dinitrophenyl-modified vaccine in, 651-652
- drug resistance in, 290-295, 311-312
- early onset of, 274
- early-stage, whole abdominal radiation in, 362-364
- endogenous hormones and, 257-258
- epidemiology for, 255-264
- epithelial, pathology of, 307-308
- exogenous hormones and, 257
- fertility drug use and, 256-257
- fertility-sparing surgery in, 327-328
- FIGO staging in, and survival, 306
- 5-year survival in, 306
- gene therapy in, 397-406
- genetic counseling in, 275
- genetic epidemiology and, 259-261
- genetics and, 265-280
- growth in, 311
- hereditary, 270-273
- histologic grade in, 307-308
- histologic subtype of, 307
- histology in, and survival, 307
- histopathology of, 255
- hysterectomy and, 258
- incidence of, 255-256, 315, 322, 326
- infertility and, 256-257
- initial surgery in, 236-237
- international distribution of, 255
- intraperitoneal chemotherapy in, 358-359
- intraperitoneal cisplatin, paclitaxel regimen in, 359
- intraperitoneal therapy for, 356-360
- invasion in, 384-385
- lactation and, 257

Ovarian cancer (*Continued*)

- laparoscopic management in, 327
- loss of heterozygosity and, 260, 269
- management of, 340-341
- mortality of, 255-256
- MRI in, 319
- multimodal screening in, 319-320
- multiple-cycle high-dose chemotherapy for, 349-355
- natural history of, 321
- new chemotherapy in, 345
- oral contraceptives and, 257, 258
- P32 in, 361-362
- paclitaxel, cisplatin regimen in, 341-343
- paclitaxel, cyclophosphamide, G-CSF regimen in, 352
- palliative radiotherapy in, 369
- parity and, 256
- patient characteristics in, 308
- peripheral blood progenitor cells in, 349-355
- physical activity and, 259
- platinum-resistant, 241
- platinum-sensitive, 241
- premalignant conditions and, 258
- previous tubal ligation and, 258
- primary cytoreduction in, 237-238
- prognostic factors in, 305-314
- proliferative fraction in, 310
- race distribution of, 256
- radiotherapy in, 361-371
- recurrent, salvage chemotherapy for, 241
- residual disease in, and survival, 329, 331
- residual tumor in, 305
- risk assessment for, 255-264
- risk factors in, 259
- risk of, algorithm for, 317
- salvage surgery in, 238
- screening for, 315-325
- second-line chemotherapy in, 344-346
- second-look laparoscopy in, 332
- second-look laparotomy in, 308, 330-332
- second-look operation in, 238
- secondary cytoreduction in, 238
- stage I, prognostic factors in, 308-309
- stage IV, cytoreduction in, 330
- staging laparotomy in, 326-327
- subsites of, 258
- surgery in, 235-238, 326-334
- surgical staging in, 237
- survival in, and residual tumor, 306
- talc and, 258-259
- time trends of, 256
- transformation and, 311
- tumor ploidy in, 310
- tumor suppressor genes in, 311
- ultrasonography in, 318-319
- unknown residual disease in, 241
- unstaged, chemotherapy for, 241
- vincristine, dactinomycin, cyclophosphamide regimen in, 239
- World Health Organization Classification of, 236

Ovarian germ cell tumor(s)

- clinical features of, 407-408
- cytoreductive surgery in, 408

Ovarian germ cell tumor(s) (*Continued*)

- initial management of, 407-408
- late effects of, 411-412
- pathology of, 408
- primary surgery in, 408
- surgical staging in, 408
- types of, 408-410

Ovary

- borderline tumors of, 372-380
- cancer-prone, 282-283
- common malignant epithelial tumors of, 286-290
- germ cell tumor of, 235-242, 407-413
- mucinous borderline tumors of, 374
- non-serous-mucinous borderline tumors of, 374
- normal epithelium of, 283-286
- serous borderline tumors of, 373-374

OVX1, in ovarian cancer, 317-318

Oxypurinol, in oral mucositis, 542

p53, 13-14

- abnormalities of, in chronic lymphocytic leukemia, 50-51
- alopecia induced by, 563
- cardiac toxicities of, 527
- controversies associated with, 343-344
- emesis risk of, 578
- for germ cell tumors, 138, 213
- intraperitoneal, 359
- oral mucositis due to, 541
- in ovarian cancer, 311, 341-343, 352
- as prognostic factor, 45
- randomized trials of, 342, 344

Parathyroid adenomatosis 1 gene, 451

Patient-controlled analgesia, in mucositis therapy, 547

Pelvic inflammatory disease, ovarian cancer and, 256-257

Penicillin-G procaine, relative toxicity of, 597

Peptide

- polyvalent vaccines v, 633-634
- for tumor vaccines, 608

Peripheral blood lymphocytosis, as prognostic factor, 45

Peripheral blood progenitor cells, in ovarian cancer, 349-355

Phase II trials, of polyvalent melanoma vaccine, 613-617

Phase III trial(s)

- of cisplatin amifostine, cyclophosphamide regimen, 522-523
- of polyvalent melanoma vaccine, 617
- of vaccinia melanoma oncolysate, 619
- of vaccinia melanoma cell lysate, 619

Physical activity, ovarian cancer and, 259

Pilocarpine, in oral mucositis, 542

Plasma cell, differentiation into, 442-443

Plasma exchange, in autoimmune hemolytic anemia, 87, 91

Platelet, vincristine-loaded, in autoimmune hemolytic anemia, 87, 91

Platelet-derived growth factor alpha, in germ cell tumors, 141-142

Platinum toxicity

- investigative agents against, 590-592
- protective agents against, 588

Pol gene, 467

Poly(a)-polymerase, as prognostic factor, 45

Polymixin B, in oral mucositis, 544

- Polyvalent melanoma vaccine, 613-617
 phase II trial of, 613-617
 phase III trial of, 617
 protocol flowsheet for, 618
 survival following, 616-617
- Polyvalent shed antigen vaccine, 618-619
- Polyvalent vaccine, peptides v, 633-634
- Poor-prognosis germ cell tumor
 cisplatin, etoposide, bleomycin regimen for, 197
 cisplatin, vinblastine, bleomycin regimen for, 197
 clinical trials of, 197
 future directions in, 200
 high-dose chemotherapy for, with hematopoietic stem cell support, 199
 nonrandomized studies in, 199-200
 pre-treatment clinical features of, 194-195
 prognostic factors in, 194
 randomized trials in, 197-199
 selected criteria in, 196
 serum tumor marker decrease in, 196-197
- Post-transplantation lymphoproliferative disease, 464-465
- Practice guidelines, in chronic lymphocytic leukemia monitoring, 53
- PRAD1, 452
- Prednisolone, cyclophosphamide, doxorubicin, vincristine regimen, in NHL, 487-489
- Prednisone, for chronic lymphocytic leukemia, 66
- Prednisone, mechlorethamine, vincristine, procarbazine regimen, in HD, 476-478
- Prednisone, methotrexate, calcium folinic acid, doxorubicin, cyclophosphamide, etoposide regimen, in NHL, 487-489
- Prednisone, methotrexate, doxorubicin, cyclophosphamide, vincristine, bleomycin regimen, in NHL, 487-489
- Primary effusion lymphoma, 471
- Primordial germ cell, in germ cell tumors, 141-142
- Procarbazine
 alopecia induced by, 563
 mechlorethamine, vincristine, prednisone regimen, in HD, 476-478
 oral mucositis due to, 541
- Prognostic factor(s)
 in metastatic germ cell tumors, 174-185
 in stage I nonseminomatous germ cell tumor, 146-147
 in stage II nonseminoma, 157
- Prognostic factor(s)
 in advanced ovarian cancer, 309
 in chronic lymphocytic leukemia, 44-47
 cytogenetic findings as, 24
 in stage I ovarian cancer, 308-309
 under investigation, in ovarian cancer, 309-310
- Prognostic index, development of, 309
- Programmed cell death, in B-cell chronic lymphocytic leukemia, 16
- Proliferating cell nuclear antigen, 46
 as prognostic factor, 45
- Proliferation antigen, as prognostic factor, 45
- Prolymphocytic leukemia, 46
 peripheral blood involvement in, 7
- Propantheline, in oral mucositis, 542
- Protein, heat-shock, 608
- Protein-DNA complex, as gene transfer vector, 665
- Proteosome, 640
- Protooncogene, c-KIT, 141
- Psychological problems, following seminoma therapy, 166
- Pure red cell aplasia
 clinical features of, 89-90
 definition of, 89
 pathophysiology of, 89
 treatment overview for, 90-92
 treatment results in, 92
- Purine analog, in chronic lymphocytic leukemia, 68
- PVB regimen, for malignant ovarian germ cell tumors, 239
- 11q13, 21
- 13q14, deletions at, 12
- 13q14 abnormality, as prognostic factor, in chronic lymphocytic leukemia, 50
- 18q21 translocation, 12
- QS-21, 609, 640
 GM2-keyhole limpet hemocyanin conjugate vaccine plus, 641
- Radiation, alopecia induced by, 568
- Radiation Therapy Oncology Group, mucositis grading of, 542
- Radioconjugates, 389-390
- Radioimmunosintigraphy, for cardiac toxicity, 528
- Radiotherapy
 for central nervous system germ cell tumors, 245
 complications of, for seminoma, 165-166
 in early-stage HD, 477
 effect of, on spermatogenesis, 227
 epoetin alfa with, 572-573
 in ovarian cancer, 361-371
 palliative, 369
 in stage I testicular seminoma, 162
 in stage II testicular seminoma, 163-164
 teratogenicity of, 230
- Ral staging system, 43, 44
 in chronic lymphocytic leukemia, 113
- RANTES, 683
- Rb1 gene, in germ cell tumors, 139
- REAL classification, of malignant lymphoma, 421-423
- Replication error(s)
 in germ cell tumors, 138
 in male germ cell tumors, 141
- Replication-defective retroviral vector, 664-665
- Rescue agents, investigative, 588
- Restriction fragment length polymorphism, in germ cell tumors, 135
- Retinoblastoma gene, in chronic lymphocytic leukemia, 50
- Retroperitoneal lymph node dissection, modified, ejaculation return following, 204
- Retroperitoneal lymph node dissection
 in stage I nonseminomatous germ cell tumor, 147-149
 semen quality and, 226-227
- Retrovirus, as gene transfer vector, 665
- Revised European-American Lymphoma classification, 421-423
- Rex protein, 467
- Ribonuclease A, as prognostic factor, 45, 46
- Richter's syndrome, 117-119
 combination chemotherapy in, 121-122

- Richter's syndrome, 117-119 (*Continued*)
Hodgkin's disease variant of, 122-123
immunosuppression and, 121
origin of, 119-121
- Risk of ovarian cancer algorithm, 317
- Royal Marsden Hospital, stage II nonseminomatous germ cell tumors in, 156-157
- Rye classification, 429
- Salvage chemotherapy
carboplatin in, 216-220
etoposide in, 216-220
issues in, for germ cell tumors, 210-211
- Scalp hypothermia, 564-565
- Screening, for cancer, *see* Cancer screening
- Second cancer, following testicular seminoma, 166, 167
- Semen, quality of, and retroperitoneal lymph node dissection, 226-227
- Seminoma, metastatic, *see* Metastatic seminoma
- Serotonin receptor antagonists, 578-579
routes of administration for, 579-580
- Sex, as prognostic factor, in chronic lymphocytic leukemia, 44
- Sezary syndrome, peripheral blood involvement in, 7
- Silver nitrate, in oral mucositis, 544
- Sodium alginate, in mucositis therapy, 547
- Sodium chloride, relative toxicity of, 597
- Sodium thiosulfate, 588, 590
- Spermatogenesis
chemotherapy and, 227-228
following seminoma therapy, 166
radiation therapy and, 227
- Splenectomy, in HD staging, 476
- Splenic lymphoma, with villous lymphocytes, 7, 423
- Splenomegaly, as prognostic factor, 45
- Staging
Binet, 43, 44, 113
cancer, and survival, 316
in chronic lymphocytic leukemia, and nursing care, 75-79
laparotomy for, 476
in ovarian cancer, 326-327
Ral, 43, 44, 113
splenectomy for, 476
surgical, in ovarian germ cell tumors, 408
- Stem cell transplantation
allogeneic versus autologous, 510
autologous, 504, 509
- Stomatitis, cryotherapy in, 542
- Stomatotoxicity
chemotherapy-induced, 538
direct, 538-539
indirect, 539-540
- Sucralfate, in mucositis therapy, 545-546
- Surgery
cytoreductive, *see* Cytoreductive surgery
desperation, in germ cell tumors, 212-213
fertility-sparing, in ovarian cancer, 327-328
interval debulking, in ovarian cancer, 332-333
for intracranial germ cell tumors, 244-245
in germ cell tumors, 203-209
in ovarian germ cell tumors, 408
salvage, in ovarian cancer, 238
- Surgery (*Continued*)
second-look, in ovarian cancer, 238
in stage I testicular seminoma, 160-162
in stage II testicular seminoma, 164
- Surveillance
in stage I nonseminomatous germ cell tumor, 149-150
in stage I testicular seminoma, 162-163
- Survival
following CancerVax, 616-617
residual disease and, in ovarian cancer, 329, 331
- t(1, 14) translocation, 13
- t(11, 14), 451-452
- T cell, activation independent of, 439-440
- T-cell-activating molecule, bispecific, 685
- T-cell activation, direct, by ex vivo gene therapy, 670
- T-cell chronic lymphocytic leukemia
peripheral blood involvement in, 7
TCL-1 gene and, 14
- T-cell costimulation, Newcastle disease virus-mediated, 682, 684
- T-cell interaction, with B cells, 31
- T-cell lymphoma, 428-429
Epstein-Barr virus-associated, 467
- T-cell lymphoproliferative disorder
NK-cell type of, 7
T-cell type of, 7
- T-cell non-Hodgkin's lymphoma, molecular genetics of, 456
- T-cell receptor structure, analysis of, 649
- T-cell receptor zeta chain, 29-30
- T-cell response, to melanoma-associated CancerVax antigens, 614
- T lymphocyte(s)
activation of, markers of, 649
characteristics of, infiltrating inflamed metastases, 649
cytokine production and, 649
subpopulations of, 385-386
- Talc, ovarian cancer and, 258-259
- Tax protein, 467
- TCL-1 gene, 14
- Teniposide, alopecia induced by, 563
- Teratogenicity, of cancer therapy, 230
- Teratoma, 133
- Testicular biopsy, patient counseling for, 230
- Testicular function, following chemotherapy, 229
- Testicular intraepithelial neoplasia, management of, 167-168
- Testicular seminoma
bilateral tumor following, 167
chemotherapy in, 163
with elevated beta-human chorionic gonadotropin, 168
follow-up management in, 167
in immunosuppressed patients, 168-169
1997 TNM classification of, 161
noncompliant patients in, 169
radiation therapy in, 162
recurrent disease in, 167
residual retroperitoneal masses in, 165
second testicular tumor following, 167
stage I, 160-163
stage II, 163-164
stage III, 164-165

- Testicular seminoma (*Continued*)
 surgery in, 160-162
 surveillance in, 162-163
 treatment complications in, 165-167
- Testis cancer
 chromosome 12 in, 134-135
 cytogenetics of, 134-135
 familial incidence of, 134
 gonadal function in, 224-233
 new TNM classification of, 191-192
- TF-R, ovarian cancer and, 382
- TGF-beta, ovarian cancer and, 382
- Theophylline, in chronic lymphocytic leukemia, 68-69
- Therapeutic response, as prognostic factor, 45
- Thioguanine
 alopecia induced by, 563
 oral mucositis due to, 541
- Thiol solution, in hair loss, 567
- Thiotepa
 alopecia induced by, 563
 oral mucositis due to, 541
- Thrombocytopenia, as prognostic factor, 45
- TNM classification
 new, of testis tumors, 191-192
 1997, of testis tumors, 161
 revision of, 131
- Tobramycin, in oral mucositis, 544
- Tocopherol
 alpha-, 565-566
 in hair loss, 567
- Topical anesthetic, in mucositis therapy, 546
- Topoisomerase I inhibitor, in chronic lymphocytic leukemia, 69-70
- Topotecan
 alopecia induced by, 563
 emesis risk of, 578
 in ovarian cancer, 345-346
- Total lymphoid irradiation, 483
- Tourniquets, in hair loss prevention, 563-564
- TP53, 455-456
- TP53 gene mutation, in germ cell tumor, 138-139
- Transcription factors, REL-NF-KB family of, 455-456
- Transferrin, ovarian cancer and, 383
- Transforming growth factor beta, 284-285
 in oral mucositis, 543
- Transforming growth factor-3, 544
- Transfusion therapy, in autoimmune hemolytic anemia, 87, 91
- Translocations,
 18q21, 12
 genetic, 13, 19, 21, 50
- Transplantation
 cytoreductive therapy prior to, 506
 lymphoma following, 457, 498-499
- Trinitrophenyl-modified syngeneic lymphocyte, 647
- Trisomy 12, 19, 21
 as prognostic factor, in chronic lymphocytic leukemia, 50
 clonal aberrations in, 22
- Tropisetron, dosing of, 579
- Troponin-I, 528-529
- Troponin-T, 528-529
- Tubal ligation, ovarian cancer and, 258
- Tumor, escape mechanisms of, 701-703
- Tumor burden, concept of, 606
- Tumor cell
 purification of, 687
 virus-modified, immunization with, 677-696
- Tumor cell infection, by Newcastle disease virus-Ulster, 680-685
- Tumor marker(s)
 biological, in germ cell tumors, 183
 in malignant ovarian germ cell tumors, 236
 post-treatment, 182-183
 role of, 244
 WHO screening criteria and, 317
- Tumor necrosis factor, 383-384
 in hair loss, 567
 ovarian cancer and, 382
- Tumor necrosis factor-alpha, 440-441, 683
- Tumor suppressor gene, 135-138
- Tumor therapy, with Newcastle disease virus, 677-678
- Tumor vaccine(s)
 adjuncts to, 608-609
 as cancer pharmacology, 662-663
 clinical approaches to, 607-608
 into clinical practice, 686-689
 cytokines and, 609
 cytokine-transduced, 661-676
 ex vivo cytokine gene-transduced, medical oncology of, 672-674
 gene-modified, clinical trials of, 662
 from heat-shock proteins, 608
 immunologic adjuvants to, 608-609
 immunopotentiating drugs and, 609
 from intact tumor cells, 607
 from peptides, 608
 from purified extracts, 607-608
 systemic antitumor effects following, 689
 from tumor cell extracts, 607
 vector development for, 663-667
- Tumor-associated antigen, 612
 melanoma-associated antigens v, 615
- Two-dimensional echocardiography, for cardiac toxicity, 528
- UCN-01, in chronic lymphocytic leukemia, 69
- Ultrasonography
 in ovarian cancer, 318-319
 premenopausal conditions detected on, 323
- Uric acid, as prognostic factor, 45
- V gene, 13, 36
- VAC regimen, for malignant ovarian germ cell tumors, 239
- Vaccina melanoma oncolysate, phase III trial of, 619
- Vaccine(s)
 adjuvant immunization with, 640
 allogeneic, 611-622
 antibodies induced by, basis for, 636-637
 autologous hapten-modified, *see* Autologous hapten-modified vaccine
 cancer, *see* Cancer vaccine
 cytokine gene-transduced, vector development for, 663-667
 development of, in ovarian cancer, 387
 ganglioside, *see* Ganglioside vaccine(s)

- Vaccine(s) (Continued)
lysate, composition of, 624-625
melanoma, 612-613
tumor, 607-608
- Vaccinia melanoma cell lysate, phase III trial of, 619
- Vaccinia virus, as gene transfer vector, 665
- Vascular endothelial growth factor, 384-385
- Vascular permeability factor, 384-385
- VDJ recombination
mechanism of, 437-438
substrate accessibility in, 438
- VH gene, 14
- Vinblastine
alopecia induced by, 563
in combination chemotherapy, for germ cell tumors, 188
emesis risk of, 578
for malignant ovarian germ cell tumors, 239
oral mucositis due to, 541
in poor-prognosis germ cell tumors, 197
- Vinblastine, doxorubicin, bleomycin, dacarbazine regimen, in HD, 477-478
- Vincristine
alopecia induced by, 563
in chronic lymphocytic leukemia, 66
emesis risk of, 578
oral mucositis due to, 541
- Vincristine, cyclophosphamide, doxorubicin, prednisolone regimen, in NHL, 487-489
- Vincristine, dactinomycin, cyclophosphamide regimen, in malignant ovarian germ cell tumors, 239
- Vincristine, mechlorethamine, procarbazine, prednisone regimen, in HD, 476-478
- Vincristine, methotrexate, calcium folinic acid, bleomycin, doxorubicin, cyclophosphamide, dexamethasone regimen, in NHL, 487-489
- Vincristine, methotrexate, doxorubicin, cyclophosphamide, prednisone, bleomycin regimen, in NHL, 487-489
- Vincristine-loaded platelets, in autoimmune hemolytic anemia, 87, 91
- Vindesine, emesis risk of, 578
- Vinorelbine
alopecia induced by, 563
emesis risk of, 578
- Vinorelbine (Continued)
in ovarian cancer, 345-346
oral mucositis due to, 541
- Viral capsid antigen, 463
- Virus
in lymphoma pathogenesis, 461-475
oncogenic, 448-449
- Virus cell surface binding, 682
- Virus xenogenization, 680
- Virus-modified tumor cell, clinical studies of, 690-693
- Vitamin C, relative toxicity of, 597
- Vitamin E, in mucositis therapy, 547
- Wales, common female cancers in, 316
- White cell count, in chronic lymphocytic leukemia, 100-101
- WHO classification, of malignant lymphoma, 421-423
- Whole abdominal radiation
adjuvant, for limited residual disease, 364-365
in advanced ovarian cancer, 364-369
as consolidation, following chemotherapy, 365-366
in ovarian cancer, 362-364
patient selection for, 364
prognostic factors and, 364
salvage, in ovarian cancer, 368-369
technique of, 366-367
toxicity of, 366-367
- Working Formulation of Non-Hodgkin's Lymphoma for Clinical Usage, 421
- World Health Organization
mucositis grading of, 542
screening criteria of, for ovarian cancer, 315-323
- World Health Organization Classification, 421-423
for germ cell tumors, 236
- WR-1065, 588
- WR2721, 587
relative toxicity of, 597
- X-linked lymphoproliferative disease, 466
Epstein-Barr virus and, 466
- Xerostomia, oral mucositis and, 541
- Yolk sac tumor, 133
- Young patient, chronic lymphocytic leukemia in, 107-116